Incidence and Risk Factors Associated with a Second Squamous Cell Carcinoma or Basal Cell Carcinoma in Psoralen + Ultraviolet A Light-treated Psoriasis Patients [PDF]
, 2002 Psoralen + ultraviolet A-treated psoriasis patients are at increased risk for squamous cell carcinomas and basal cell carcinomas; however, the incidence and risk factors associated with second squamous cell carcinomas and basal cell carcinomas in this ...
Katz, Kenneth A. +2 more
core +1 more source
IL‐17 and IL‐23 inhibitors dose spacing in adult psoriatic patients: a real‐world pilot study
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.Summary Background and Objectives De‐escalation strategies of biologics in psoriasis treatment are widespread in clinical practice. Dose spacing consists of de‐escalating the time range between biological drug injections. Patients and Methods Major objectives were: to describe trends in mean PASI, PASI 100, 90, and ≤ 1 from baseline to 12 months after ...
Luca Mastorino +5 more
wiley +1 more source
Platelet-activating factor is crucial in psoralen and ultraviolet A-induced immune suppression, inflammation, and apoptosis. [PDF]
, 2006 Psoralen plus UVA (PUVA) is used as a very effective treatment modality for various diseases, including psoriasis and cutaneous T-cell lymphoma. PUVA-induced immune suppression and/or apoptosis are thought to be responsible for the therapeutic action ...
Ananthaswamy, Honnavara N +8 more
core +2 more sources
European Guideline (EuroGuiDerm) on atopic eczema: Living update
Journal of the European Academy of Dermatology and Venereology, EarlyView.The updated guideline includes a new evidence‐based recommendation for the IL‐13 inhibitor lebrikizumab. In addition, the Janus kinase inhibitors baricitinib and abrocitinib, which were initially only approved for adult patients, are now also recommended for children from the age of 2 and adolescents from the age of 12, respectively.
A. Wollenberg +31 more
wiley +1 more source
Tracing the Photoaddition of Pharmaceutical Psoralens to DNA
Molecules, 2020 The psoralens 8-methoxypsoralen (8-MOP), 4,5′,8-trimethylpsoralen (TMP) and 5-methoxypsoralen (5-MOP) find clinical application in PUVA (psoralen + UVA) therapy. PUVA treats skin diseases like psoriasis and atopic eczema.
Janina Diekmann +3 more
doaj +1 more source
Methoxsalen-induced macular toxicity
Indian Journal of Ophthalmology, 2017 Psoralen compounds such as methoxsalen are photosensitizer agents used in conjunction with ultraviolet A (UVA) radiation exposure as photochemotherapy (Psoralens and ultraviolet-A therapy [PUVA therapy]) for certain epidermal skin disorders such as ...
Aditya Maitray, Pukhraj Rishi
doaj +1 more source
Blocking or enhancing effects of some basic emollients in UVA penetration [PDF]
Anais Brasileiros de Dermatologia, 2018 : Background: Topical agents used in combination with phototherapy or photochemotherapy may have both blocking or enhancing effects in ultraviolet rays.
Sevgi Akarsu +3 more
doaj +1 more source
Clinical patterns of vitiligo in Japan: A descriptive study using the JMDC claims database
The Journal of Dermatology, Volume 52, Issue 5, Page 831-840, May 2025.Abstract Vitiligo is a chronic autoimmune disorder that profoundly impacts patients' quality of life. Real‐world data on vitiligo in Japan are limited. This descriptive, cross‐sectional study used a claims database to evaluate vitiligo prevalence, patient demographics, treatments, and comorbidities in Japanese patients with vitiligo.
Atsushi Tanemura +5 more
wiley +1 more source
PuVAE: A Variational Autoencoder to Purify Adversarial Examples [PDF]
arXiv, 2019 Deep neural networks are widely used and exhibit excellent performance in many areas. However, they are vulnerable to adversarial attacks that compromise the network at the inference time by applying elaborately designed perturbation to input data. Although several defense methods have been proposed to address specific attacks, other attack methods can
arxiv
Optimal personalized therapies in colon-cancer induced immune response using a Fokker-Planck framework [PDF]
arXiv, 2022 In this paper, a new stochastic framework to determine optimal combination therapies in colon cancer-induced immune response is presented. The dynamics of colon cancer is described through an It\"o stochastic process, whose probability density function evolution is governed by the Fokker-Planck equation.
arxiv